



Universiteit  
Leiden

The Netherlands

## From labelled to the optimal clinical dose: model-informed dose optimization in medical oncology practice

Tan, Z.

### Citation

Tan, Z. (2026, March 31). *From labelled to the optimal clinical dose: model-informed dose optimization in medical oncology practice*. Retrieved from <https://hdl.handle.net/1887/4299937>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/4299937>

**Note:** To cite this publication please use the final published version (if applicable).

**From labelled to the optimal clinical dose:  
Model-informed dose optimization in  
medical oncology practice**

**Zhiyuan Tan**

The research described in this thesis was performed at the division Systems Pharmacology and Pharmacy of the Leiden Academic Centre for Drug Research (LACDR), Leiden University (Leiden, The Netherlands) and the Department of Clinical Pharmacy and Toxicology of Leiden University Medical Center (Leiden, The Netherlands). The research was financially supported by China Scholarship Council (CSC).

**Layout**                 Renate Siebes | Proefschrift.nu  
**Printed by**            Proefschriftmaken.nl | De Bilt  
**ISBN**                    978-94-6534-241-2

© 2026 Zhiyuan Tan

All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronically or mechanically, including photocopying, recording or in any information storage or retrieval system, without prior permission of the author.

# **From labelled to the optimal clinical dose: Model-informed dose optimization in medical oncology practice**

## **Proefschrift**

ter verkrijging van  
de graad van doctor aan de Universiteit Leiden,  
op gezag van rector magnificus prof. dr. S. de Rijcke,  
volgens besluit van het college voor promoties  
te verdedigen op dinsdag 31 maart 2026  
klokke 10:00 uur

door

**Zhiyuan Tan**

geboren te Jiangsu, China  
in 1995

**Promotor** Prof. dr. C.A.J. Knibbe

**Co-promotores** Dr. D.J.A.R. Moes, Leiden University Medical Center  
Dr. S. Völler

**Promotiecommissie** Prof. dr. M. van Eck  
Prof. dr. E.C.M. de Lange  
Prof. dr. N.P. van Erp, Radboud University Medical Center  
Prof. dr. T. van Gelder, Leiden University Medical Center  
Prof. dr. J.G.C. van Hasselt  
Dr. S.L.W. Koolen, Erasmus Medical Center

# Contents

<b>Section I</b>	<b>Background and introduction</b>	
<b>Chapter 1</b>	General introduction and scope of the investigations	<b>9</b>
<b>Section II</b>	<b>Closing the gap between the labelled and optimal clinical dose with publicly available data</b>	
<b>Chapter 2</b>	A systematic evaluation of the dosing regimens for approved targeted therapies and immune checkpoint inhibitors in metastatic renal cell carcinoma from a Project OPTIMUS perspective	<b>23</b>
<b>Section III</b>	<b>Model-informed dose optimization of targeted therapies with real-world patient data</b>	
<b>Chapter 3</b>	Population pharmacokinetics of cabozantinib in metastatic renal cell carcinoma patients: Towards drug expenses saving regimens	<b>67</b>
<b>Chapter 4</b>	Model-informed dose optimization of pazopanib in real-world patients with cancer	<b>97</b>
<b>Section IV</b>	<b>Model-informed dose optimization in chemotherapy and immunotherapy</b>	
<b>Chapter 5</b>	Advancing precision dosing of 5-FU: Population PK model development, limited sampling strategies and fit-for-use application	<b>141</b>
<b>Chapter 6</b>	Characterization of real-world pembrolizumab population pharmacokinetics in cancer patients: Towards identification of non-responders using change in clearance as efficacy biomarker and individualization of the dosing interval	<b>185</b>
<b>Section V</b>	<b>General discussion</b>	
<b>Chapter 7</b>	General discussion and future perspectives	<b>225</b>
	Samenvatting	<b>245</b>
	Acknowledgements	<b>251</b>
	Curriculum Vitae	<b>259</b>
	List of publications	<b>260</b>